Table S1: EC50 information of rituximab, polatuzumab vedotin, the unconjugated scientific antibody, surrogate ADC, as well as the unconjugated surrogate antibody from person binding experiments with human Fcγ https://mayamseg476899.wikiannouncement.com/user